MX2020005247A - Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico. - Google Patents
Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico.Info
- Publication number
- MX2020005247A MX2020005247A MX2020005247A MX2020005247A MX2020005247A MX 2020005247 A MX2020005247 A MX 2020005247A MX 2020005247 A MX2020005247 A MX 2020005247A MX 2020005247 A MX2020005247 A MX 2020005247A MX 2020005247 A MX2020005247 A MX 2020005247A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- administration
- immune responses
- modulation
- responses related
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a métodos de preparación ce una formulación farmacéutica que comprende un fármaco biofarmacéutico, dichos métodos permite la modulación de las respuestas inmunitarias relacionadas con la administración de la misma. La formulación comprende un regulacor de pH que comprende ácido hexanodioico o por lo menos una sal del mismo, y/o ácido cítrico o por lo menos una sal del mismo. La presente invención se refiere además a un método de uso de ácido hexanodioico o por lo menos una sal del mismo, y/o ácido cítrico o por lo menos una sal del mismo, para modular la inmunogenicidad de una formulación farmacéutica, a una formulación farmacéutica como tal, y a métodos de modulación o determinación de respuestas inmunitarias relacionadas con la administración de una formulación farmacéutica (Figura 4).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13177259 | 2013-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005247A true MX2020005247A (es) | 2020-08-24 |
Family
ID=48794008
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000405A MX380569B (es) | 2013-07-19 | 2014-07-21 | Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico. |
| MX2020005247A MX2020005247A (es) | 2013-07-19 | 2016-01-12 | Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000405A MX380569B (es) | 2013-07-19 | 2014-07-21 | Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160151484A1 (es) |
| EP (1) | EP3021833B2 (es) |
| JP (2) | JP2016525110A (es) |
| CN (1) | CN105377237B (es) |
| AU (1) | AU2014291970B2 (es) |
| BR (1) | BR112016000563A2 (es) |
| CA (1) | CA2914776C (es) |
| ES (1) | ES2688726T5 (es) |
| MX (2) | MX380569B (es) |
| RU (1) | RU2662558C2 (es) |
| SI (1) | SI3021833T2 (es) |
| WO (1) | WO2015007912A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| HK1207960A1 (en) | 2013-03-12 | 2016-02-19 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| HUE026793T2 (en) * | 2003-10-01 | 2016-07-28 | Kyowa Hakko Kirin Co Ltd | A method for stabilizing an antibody and a stabilized solution-type antibody preparation |
| GB0503337D0 (en) * | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
| US20100278822A1 (en) * | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| US8821865B2 (en) | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
| EP2471554A1 (en) * | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| RU2683020C2 (ru) * | 2014-11-11 | 2019-03-26 | Петр Иванович Никитин | Субстанция и способ для модуляции активности агента в организме |
-
2014
- 2014-07-21 WO PCT/EP2014/065612 patent/WO2015007912A1/en not_active Ceased
- 2014-07-21 AU AU2014291970A patent/AU2014291970B2/en not_active Ceased
- 2014-07-21 SI SI201430872T patent/SI3021833T2/sl unknown
- 2014-07-21 RU RU2016105462A patent/RU2662558C2/ru active
- 2014-07-21 ES ES14744505T patent/ES2688726T5/es active Active
- 2014-07-21 US US14/905,689 patent/US20160151484A1/en not_active Abandoned
- 2014-07-21 JP JP2016526663A patent/JP2016525110A/ja active Pending
- 2014-07-21 CA CA2914776A patent/CA2914776C/en not_active Expired - Fee Related
- 2014-07-21 EP EP14744505.0A patent/EP3021833B2/en active Active
- 2014-07-21 CN CN201480040059.1A patent/CN105377237B/zh active Active
- 2014-07-21 BR BR112016000563A patent/BR112016000563A2/pt not_active Application Discontinuation
- 2014-07-21 MX MX2016000405A patent/MX380569B/es unknown
-
2016
- 2016-01-12 MX MX2020005247A patent/MX2020005247A/es unknown
-
2017
- 2017-08-24 JP JP2017160728A patent/JP6797767B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX380569B (es) | 2025-03-12 |
| MX2016000405A (es) | 2016-09-09 |
| ES2688726T5 (es) | 2022-06-27 |
| CA2914776C (en) | 2018-08-07 |
| CA2914776A1 (en) | 2015-01-22 |
| EP3021833B1 (en) | 2018-06-27 |
| US20160151484A1 (en) | 2016-06-02 |
| JP6797767B2 (ja) | 2020-12-09 |
| AU2014291970B2 (en) | 2017-09-28 |
| CN105377237A (zh) | 2016-03-02 |
| BR112016000563A2 (pt) | 2017-09-05 |
| CN105377237B (zh) | 2019-04-19 |
| SI3021833T1 (sl) | 2018-10-30 |
| SI3021833T2 (sl) | 2022-08-31 |
| EP3021833B2 (en) | 2022-03-30 |
| EP3021833A1 (en) | 2016-05-25 |
| RU2662558C2 (ru) | 2018-07-26 |
| ES2688726T3 (es) | 2018-11-06 |
| JP2018012716A (ja) | 2018-01-25 |
| AU2014291970A1 (en) | 2016-01-28 |
| WO2015007912A1 (en) | 2015-01-22 |
| JP2016525110A (ja) | 2016-08-22 |
| RU2016105462A (ru) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005247A (es) | Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico. | |
| EA201890817A1 (ru) | Кристаллические формы бета-никотинамида мононуклеотида | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| BR112017004393A2 (pt) | formulações de anticorpo | |
| MX2017005575A (es) | Formulacion farmaceutica de anticuerpos anti-tnf alfa. | |
| EA201691978A1 (ru) | Соединения в качестве модуляторов ror гамма | |
| EP4285928A3 (en) | Anti-pdl1 antibody formulations | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| MX2016005395A (es) | Formulacion estable de insulina glulisina. | |
| AU2017242867A8 (en) | Vortioxetine pamoic acid salt and crystal form thereof | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| EP4480544A3 (en) | Immunomodulatory compositions andmethods of use thereof | |
| EP4218823A3 (en) | Novel polymeric hgh prodrugs | |
| AU2014375637A1 (en) | Formula of neuregulin preparation | |
| WO2015020913A3 (en) | Influenza hemagglutinin proteins and methods of thereof | |
| BR112017014994A2 (pt) | formulação em pó nasal para o tratamento de hipoglicemia | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| MX377919B (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
| MX385925B (es) | Oritavancina de alta pureza y método para producir la misma. | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
| PH12015502556A1 (en) | Modified release formulation | |
| TW201613557A (en) | Stable aqueous recombinant protein formulations | |
| EA201691741A1 (ru) | Фармацевтическая композиция | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída |